Kyle Clifford was sitting across from a headhunter when the name dropped: amfAR. What the recruiter didn’t know, what almost nobody knew, was that Clifford was HIV positive and that amfAR’s research had helped keep him alive.

“I said, I will meet them tomorrow,” Clifford recalls. “For me, it was full circle. I have an opportunity here to join an organization that has helped keep me alive.”

Five and a half years later, Clifford is amfAR’s CEO, the first in the organization’s 40-year history who is openly living with HIV. And the story he’s telling stretches far beyond the virus that changed his life.

The Ripple Effect No One Talks About

Here’s what most people miss about HIV research: it has quietly reshaped modern medicine for everyone. Cancer immunotherapy, the mRNA platform behind the COVID-19 vaccine, long-acting drug delivery systems now being adapted for hormonal therapies and mental health treatment, CRISPR and CAR T-cell breakthroughs. All of it traces back to what researchers learned trying to defeat HIV.

“Whether someone in your household has experience with HIV or not,” Clifford says, “our work has impacted every household in America.”

That broader impact is now driving amfAR’s strategy. The organization is expanding its research investments into areas where HIV science intersects with cardiovascular disease, Alzheimer’s, and cancer, particularly as the aging HIV-positive population presents research opportunities with implications well beyond the virus itself. It’s not mission drift. It’s mission depth. The researchers told amfAR they were already doing this work. They just needed more funding.

The Venture Capital of Science

What sets amfAR apart isn’t only what it funds. It’s how. Clifford describes the model as catalytic funding, the biomedical equivalent of seed capital for entrepreneurs. A researcher with a bold idea who needs $250,000 to test it doesn’t have to navigate institutional bureaucracy or local politics. They come to amfAR.

“You’ll hear entrepreneurs talk about the person who gave them their first loan. They needed someone to believe in them. That’s exactly what amfAR does.”

The demand tells the story. Grant applications have surged 20x in the past year. At a recent conference of 3,200 retrovirus experts, senior researchers approached Clifford to express something simple: gratitude. Their first fellowship, their first lab grant, the funding that launched their careers came from amfAR.

And every dollar is private. amfAR receives no state or federal funding. It is 100% dependent on philanthropy, which in this environment may be less a vulnerability than a strength. As Clifford puts it, “We’ve had to hustle. That’s what we’ve always done.”

The Finish Line Is Visible

Ten people have now been defined as cured of HIV. Researchers are pursuing three strategies against the virus’s latent reservoirs: kick and kill, which flushes the virus out; block and lock, which pushes it deeper into dormancy; and gene editing through CRISPR, which aims to cut HIV’s genetic code from infected cells.

Yet complacency remains a real threat. “Some would even use the word cure,” Clifford says. “Isn’t it cured? I hear it all the time.” It isn’t. There are still 1.6 million new infections annually.

Without daily medication, Clifford’s own virus would reemerge.

But the finish line is visible. “We’ve done this marathon since 1985,” he says. “We’re going into Central Park for that last two, three miles. That’s when you really need to dig deep.”

Hope as Currency

Before the headhunter’s call, before any of it, Clifford was a young man walking out of a doctor’s clinic with a diagnosis that terrified him. The medication was essential. But something else carried equal weight.

“There is one thing that you cling on to,” he says, “and that was hope.”

That hope, the knowledge that researchers were fighting for a solution, is what amfAR provides alongside its grants. It’s what Clifford channels into every meeting, every gala from London to Palm Beach to Las Vegas, and every conversation with a prospective donor who isn’t sure their contribution matters.

It does. Whether it’s $50 a month or a transformational gift from a family foundation, it reaches a researcher in a lab with an idea that could change everything. And now it reaches them through a CEO who is living proof that the investment pays off.

To learn more or support amfAR’s work, visit amfar.org or connect with Kyle Clifford directly on LinkedIn.


Every weekday morning at 7:00 a.m. Eastern, I publish a short Leadership Note from the Field. These reflections draw on fifty years in the nonprofit sector and nearly 1,000 conversations with nonprofit leaders.
They are designed to help leaders step back from the noise, see the deeper pattern, and lead with greater clarity. A recent note explores a distinction I believe matters enormously right now. In philanthropy, don’t confuse headlines with forces. Headlines dominate the moment. But deeper forces such as the $124 trillion wealth transfer, the rise of women as philanthropic decision makers, and the growth of giving across the Global South will shape the next twenty-five years. You can read the full note, along with a new one posted every weekday morning, on my blog at denver-frederick.com or on LinkedIn.

Share This: